Development of the controlled release- medicine for pain treatment using drug delivery system.

使用药物输送系统开发用于疼痛治疗的控释药物。

• 批准号: 23890027
• 负责人: SUZUKI Toshiyuki
• 金额: $ 1.91万
• 依托单位: Gunma University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Research Activity Start-up
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-23890027/
• 关键词: ドラッグデリバリーシステム; 徐放薬; 鼻粘膜; 臨床試験; リドカイン; 正常粘膜; クロロホルム; PLGA; ビーグル犬; 臨床応用; 尿道カテーテル; 抜歯後疼痛; Drug Delivery System

The controlled release- lidocaine sheet significantly raised mean pain thresholds in a nasal mucous membrane compared with that of preadministration more than 72 hours. Feeling a pain by some pressure stimulation suggested that lidocaine of the component could not reach subcutaneous tissue, but only an outer layer of a mucous membrane. As for side effects, almost all had reactive serous rhinorrhea, but obvious serious adverse events such as a liver injury, a renal injury, pancytopenia and the other were not observed. It may be possible to lead a single administration of the controlled release- lidocaine sheet to the simple and effective postoperative analgesia with few side effects in future.

与给药前相比，控释利多卡因片显著提高鼻粘膜的平均痛阈超过72小时。通过一些压力刺激感觉到疼痛，表明该成分的利多卡因不能到达皮下组织，而只能到达粘膜的外层。至于副作用，几乎所有的反应性浆液性白带，但没有观察到明显的严重不良事件，如肝损伤，肾损伤，全血细胞减少等。利多卡因控释片的单次给药有可能成为一种简单、有效、副作用少的术后镇痛方法。